Ticagrelor is not superior to clopidogrel in reducing periprocedural ischemic events during elective percutaneous coronary intervention (PCI) in stable patients, according to late-breaking-trial results presented Saturday at the American Heart Association (AHA) Scientific Sessions 2020 virtual conference.